论文部分内容阅读
目的 评估以米托蒽醌为主联合化疗方案治疗急性白血病的疗效。方法 对血液科住院的白血病 (M3 除外 )采用以米托蒽醌为主联合化疗方案进行治疗 ,共计 5 5例 ,其中复发者 5例 ,用VMP方案治疗ALL19例、MA方案治疗ANLL34例 ,CML急性变 2例。结果 初治急性白血病患者CR为 2 3例 ,CR率达 46 % ,PR为 16例 ,PR率为32 % ,总有效率达 78% ,5例复发者 3例达CR。结论 以米托蒽醌为主的化疗方案 (VMP、MA)治疗急性白血病有效 ,且副作用不大 ,病人能耐受。值得临床推广应用。
Objective To evaluate the efficacy of mitoxantrone-based chemotherapy in the treatment of acute leukemia. Methods A total of 55 cases were treated with mitoxantrone-based chemotherapy in leukemia hospitalized with hematology (excluding M3), including 5 cases of relapse, 19 cases of ALL treated with VMP regimen, 34 cases of ANLL treated with MA regimen, CML Acute change in 2 cases. Results The CR of CR patients was 46%, the PR was 16, the PR rate was 32%, the total effective rate was 78%, and 5 of 5 relapsed patients reached CR. Conclusion Mitoxantrone-based chemotherapy (VMP, MA) is effective in the treatment of acute leukemia with little side effects and is tolerant to the patients. Worthy of clinical application.